Skip to main content
. 2013 Dec 10;2(2):212–218. doi: 10.3892/mco.2013.223

Figure 1.

Figure 1

Comparison of progression-free survival (PFS) between the platinum (Pt) and non-Pt groups during the observation period of all histological types. Patients who relapsed (A) <6 months, (B) 6–12 months and (C) ≥12 months after the first-line treatment.